Inmune Bio, Inc.
INMBNasdaq
$1.90
↓ -8.2%Jul 17 close · end-of-day
Price
1Y↓ -18.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$50.5M
Enterprise Value
$50.5M
P/E
—
P/S
—
P/B
2.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$41.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-212.3%
ROIC
-174.3%
Debt / Equity
—
Net Cash
—
Return 1Y
-15.2%
Company profile
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
- CEO
- Raymond J. Tesi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- Florida
- Website
- inmunebio.com
Management & directors
- Lowdell Mark WilliamChief Scientific Officer
- Moss David JChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
INMB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.20↓ -53.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $11,000.00 | $181,000.00 | $374,000.00 | $155,000.00 | $14,000.00 | $50,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$12.2M | -$29.2M | -$26.0M | -$29.7M | -$42.6M | -$47.4M |
| Net income | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.0M | -$46.0M |
| Diluted EPS | — | -$1.88 | -$1.52 | -$1.67 | -$2.11 | -$1.86 |
| Operating cash flow | -$8.9M | -$28.5M | -$22.7M | -$12.0M | -$33.4M | -$22.6M |
| Free cash flow | — | — | — | — | — | -$23.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -111163.6% | -16106.6% | -6938.8% | -19187.7% | -304535.7% | -94766.0% |
| Net margin | -109990.9% | -16762.4% | -7299.2% | -19354.8% | -300000.0% | -92000.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $50,000.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.9M | -$12.3M | -$9.5M | -$9.9M | -$24.6M | -$7.4M | -$5.5M | -$5.8M |
| Net income | -$9.7M | -$12.1M | -$9.1M | -$9.7M | -$24.5M | -$6.5M | -$5.3M | -$5.4M |
| Diluted EPS | -$0.50 | -$0.60 | -$0.40 | -$0.43 | -$1.05 | -$0.24 | -$0.14 | -$0.20 |
| Operating cash flow | -$7.9M | -$7.0M | -$11.0M | -$6.8M | -$7.4M | -$5.4M | -$2.9M | -$3.4M |
| Free cash flow | — | — | — | — | — | -$5.6M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | -19810.0% | — | — | — | — |
| Net margin | — | — | — | -19478.0% | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Juda Scott | Option exercise | 14,801 | $1.40 | $20,721.40 | filing |
| 2026-07-02 | Moss David J· Chief Executive Officer | Option exercise | 9,014 | $1.40 | $12,619.60 | filing |
| 2026-07-02 | Lowdell Mark William· Chief Scientific Officer | Option exercise | 7,211 | $1.40 | $10,095.40 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.